Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020
Adverse Effects of Antiretroviral Therapy
Lancet 356:1423-1430, Carr,A. &Cooper, D.A., 2000
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
Lipodystrophy Associated with an HIV-Protease Inhibitor
NEJM 339:1296, Carr,A.&Cooper,D.A., 1998
Buffalo Hump in a Patient with the Acquired Immunodeficiency Syndrome
NEJM 339:1297, Aboulafia,D.M.&Bundow,D., 1998
Toxoplasmosis in HIV-Infected Patients
www.UptoDate.com, May, Gandhi, R.T., 2019
The Importance of Lesbian, Gay, Bisexual and Transgender Health in Neurology
JAMA Neurol 72:855, Rosendale, N. & Josephson, S.A., 2015
Preexposure Prophylaxis for HIV - Where Do We Go from Here?
NEJM 367:459-461,462, Cohen, M.S. & Baden, L.R., 2012
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
NEJM 365:493-505,561, Cohen, M.S.,et al, 2011
PML-IRIS in Patients with HIV Infection: Clinical Manifestations and Treatment with Steroids
Neurol 72:1458-1464,1454, Tan,K.,et al, 2009
Reversible Posterior Leukoencephalopathy Syndrome in 2 HIV-Infected Patients Receiving Antiretroviral Therapy
CID 49:e19-e22, Ridolfo, A.L.,et al, 2008
Cerebral MR Imaging in Uninfected Children Born to HIV-Seropositive Mothers and Perinatally Exposed to Zidovudine
AJNR 26:695-701,687, Tardieu,M.,et al, 2005
Prospective Study of New-Onset Seizures in Patients with Human Immunodeficiency Virus Infection
Arch Neurol 56:609-612, Pascual-Sedano,B.,et al, 1999
Tremor Caused by Trimethoprim-Sulfamethoxazole in a Patient with AIDS
Neurol 48:537-538, VanGerpen,J.A., 1997
Hearing Loss and Antiretroviral Therapy in Patients Infected with HIV-1
Arch Neurol 54:407-410, Marra,C.M.,et al, 1997
Acute Rhabdomyolysis in Patients Infected by Human Immunodeficiency Virus
Neurol 44:1692-1696, Chariot,P.,et al, 1994
Therapy for Human Immunodeficiency Virus Infection
NEJM 328:1686-1695, Hirsch,M.S.&D'Aquila,R., 1993
Treatment of Toxoplasmic Encephalitis in Patients with AIDS, Pyrimethamine & Clindamycin vs. Pyrimethamine & Sulfadiazine
Ann Int Med 116:33-43, Dannemann,B.,et al, 1992
Toxicity of Clindamycin as Prophylaxis for AIDS-Associated Toxoplasmic Encephalitis
Lancet 339:333-334, Jacobson,M.A.,et al, 1992
Mortality in Patients with AIDS Treated with Either Foscarnet or Ganciclovir for CMV Retinitis
AIDS Res Group & AIDS Clin Trials Group, NEJM 326:213-220, 2642., , 1992
Toxoplasma Encephalitis in Patients with the Acquired Immunodeficiency Syndrome
Medicine 71:224-239, Renold,C.,et al, 1992
Low-Dose Trimethoprim-Sulfamethoxazole Prophylaxis for Toxoplasmic Encephalitis in Patients with AIDS
Ann Int Med 117:106-111, 163-1641992., Carr,A.,et al, 1992
Efficacy of Atovaquone in Treatment of Toxoplasmosis in Patients with AIDS
Lancet 340:637-638, Kovacs,J.A., 1992
Toxoplasmosis of the Central Nervous System in the Acquired Immunodeficiency Syndrome
NEJM 327:1643-1648, Porter,S.B.&Sande,M.A., 1992
Extrapyramidal side Effects of Antiemetics Presenting as Psychiatric Illness
Gen Hosp Psychiatry 14:192-195, Rodgers,C., 1992
Myopathy in Human Immunodeficiency Virus-Infected Children Receiving Long-Term Zidovudine Therapy
J Pediatr 119:152-155, Walter,E.B.,et al, 1991
Zidovudine Myopathy:A Distinctive Disorder Associated with Mitochondrial Dysfunction
Ann Neurol 29:606-614, Mhiri,C.,et al, 1991
Diphenylhydantoin-Induced Hypogammaglobulinemia in a Patient Infected with Human Immunodeficiency Virus
Am J Med 90:524-527, Britigan,B.E., 1991
A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Pts with AIDS
Ann Int Med 115:665-673, Palestine,A.G.,et al, 1991
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
NEJM 354:924-933,965, Yousry,T.A.,et al, 2006
Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023
A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019